Matches in DBpedia 2014 for { <http://dbpedia.org/resource/Eribulin> ?p ?o. }
Showing items 1 to 68 of
68
with 100 items per page.
- Eribulin abstract "Eribulin is an anticancer drug marketed by Eisai Co. under the trade name Halaven. Eribulin mesylate was approved by the U.S. Food and Drug Administration on November 15, 2010, to treat patients with metastatic breast cancer who have received at least two prior chemotherapy regimens for late-stage disease, including both anthracycline- and taxane-based chemotherapies. It was approved by Health Canada on December 14, 2011 for treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease.Eribulin is also being investigated by Eisai Co. for use in a variety of other solid tumors, including non-small cell lung cancer, prostate cancer and sarcoma.Eribulin has been previously known as E7389 and ER-086526, and also carries the US NCI designation NSC-707389.".
- Eribulin atcPrefix "L01".
- Eribulin atcSuffix "XX41".
- Eribulin casNumber "253128-41-5".
- Eribulin fdaUniiCode "LR24G6354G".
- Eribulin iupacName "2-(3-Amino-2-hydroxypropyl)hexacosahydro-3-methoxy- 26-methyl-20,27-bis(methylene)11,15-18,21-24,28-triepoxy- 7,9-ethano-12,15-methano-9H,15H-furo(3,2-i)furo(2',3'-5,6) pyrano(4,3-b)(1,4)dioxacyclopentacosin-5-(4H)-one".
- Eribulin pubchem "17755248".
- Eribulin thumbnail Eribulin.svg?width=300.
- Eribulin wikiPageID "15623623".
- Eribulin wikiPageRevisionID "596783728".
- Eribulin atcPrefix "L01".
- Eribulin atcSuffix "XX41".
- Eribulin c "40".
- Eribulin casNumber "253128".
- Eribulin chembl "1237028".
- Eribulin chemspiderid "21396142".
- Eribulin h "59".
- Eribulin hasPhotoCollection Eribulin.
- Eribulin inchi "1".
- Eribulin inchikey "VEPHOPLDBFLPDL-KVWSPMLQBN".
- Eribulin iupacName "2".
- Eribulin legalUs "Rx-only".
- Eribulin licenceUs "Eribulin".
- Eribulin medlineplus "a611007".
- Eribulin molecularWeight "729.9".
- Eribulin n "1".
- Eribulin o "11".
- Eribulin pregnancyUs "D".
- Eribulin pubchem "17755248".
- Eribulin routesOfAdministration "Intravenous".
- Eribulin smiles "NC[C@@H]C[C@H]5O[C@H]4C[C@H]9O[C@@H]C[C@@H]C9=C".
- Eribulin stdinchi "1".
- Eribulin stdinchikey "VEPHOPLDBFLPDL-KVWSPMLQSA-N".
- Eribulin tradename "Halaven".
- Eribulin unii "LR24G6354G".
- Eribulin verifiedfields "changed".
- Eribulin verifiedrevid "461094948".
- Eribulin watchedfields "changed".
- Eribulin width "300".
- Eribulin subject Category:Antineoplastic_drugs.
- Eribulin type Agent114778436.
- Eribulin type Antineoplastic102722458.
- Eribulin type AntineoplasticDrugs.
- Eribulin type CausalAgent100007347.
- Eribulin type CytotoxicDrug103157987.
- Eribulin type Drug103247620.
- Eribulin type Matter100020827.
- Eribulin type Medicine103740161.
- Eribulin type PhysicalEntity100001930.
- Eribulin type Substance100020090.
- Eribulin type Drug.
- Eribulin type DrugProduct.
- Eribulin type FunctionalSubstance.
- Eribulin comment "Eribulin is an anticancer drug marketed by Eisai Co. under the trade name Halaven. Eribulin mesylate was approved by the U.S. Food and Drug Administration on November 15, 2010, to treat patients with metastatic breast cancer who have received at least two prior chemotherapy regimens for late-stage disease, including both anthracycline- and taxane-based chemotherapies.".
- Eribulin label "Eribulin".
- Eribulin label "Eribulin".
- Eribulin label "Eribulina".
- Eribulin label "エリブリン".
- Eribulin sameAs Eribulin.
- Eribulin sameAs エリブリン.
- Eribulin sameAs Eribulina.
- Eribulin sameAs m.03mj0sv.
- Eribulin sameAs Q408717.
- Eribulin sameAs Q408717.
- Eribulin sameAs Eribulin.
- Eribulin wasDerivedFrom Eribulin?oldid=596783728.
- Eribulin depiction Eribulin.svg.
- Eribulin isPrimaryTopicOf Eribulin.
